Literature DB >> 33319463

Piptides: New, Easily Accessible Chemotypes For Interactions With Biomolecules.

Maritess Arancillo1, Jaru Taechalertpaisarn1, Xiaowen Liang2, Kevin Burgess1.   

Abstract

Small molecule probe development is pivotal in biomolecular science. Research described here was undertaken to develop a non-peptidic chemotype, piptides, that is amenable to convenient, iterative solid-phase syntheses, and useful in biomolecular probe discovery. Piptides can be made from readily accessible pip acid building blocks and have good proteolytic and pH stabilities. An illustrative application of piptides against a protein-protein interaction (PPI) target was explored. The Exploring Key Orientations (EKO) strategy was used to evaluate piptide candidates for this. A library of only 14 piptides contained five members that disrupted epidermal growth factor (EGF) and its receptor, EGFR, at low micromolar concentrations. These piptides also caused apoptotic cell death, and antagonized EGF-induced phosphorylation of intracellular tyrosine residues in EGFR.
© 2020 Wiley-VCH GmbH.

Entities:  

Keywords:  EGF; cancer; peptidomimetics; protein-protein interactions; solid-phase synthesis

Mesh:

Substances:

Year:  2021        PMID: 33319463      PMCID: PMC7940574          DOI: 10.1002/anie.202015203

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN: 1433-7851            Impact factor:   15.336


  67 in total

1.  Improving oral bioavailability of peptides by multiple N-methylation: somatostatin analogues.

Authors:  Eric Biron; Jayanta Chatterjee; Oded Ovadia; Daniel Langenegger; Joseph Brueggen; Daniel Hoyer; Herbert A Schmid; Raz Jelinek; Chaim Gilon; Amnon Hoffman; Horst Kessler
Journal:  Angew Chem Int Ed Engl       Date:  2008       Impact factor: 15.336

Review 2.  Peptoids as potential therapeutics.

Authors:  Ronald N Zuckermann; Thomas Kodadek
Journal:  Curr Opin Mol Ther       Date:  2009-06

3.  EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization.

Authors:  Kathryn M Ferguson; Mitchell B Berger; Jeannine M Mendrola; Hyun Soo Cho; Daniel J Leahy; Mark A Lemmon
Journal:  Mol Cell       Date:  2003-02       Impact factor: 17.970

4.  ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression.

Authors:  N G Anderson; T Ahmad; K Chan; R Dobson; N J Bundred
Journal:  Int J Cancer       Date:  2001-12-15       Impact factor: 7.396

5.  Development of homomultimers and heteromultimers of lung cancer-specific peptoids.

Authors:  Jared C Hooks; Jaya P Matharage; D Gomika Udugamasooriya
Journal:  Biopolymers       Date:  2011       Impact factor: 2.505

Review 6.  Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.

Authors:  William Pao; Vincent A Miller
Journal:  J Clin Oncol       Date:  2005-03-14       Impact factor: 44.544

Review 7.  ERBB receptors and cancer: the complexity of targeted inhibitors.

Authors:  Nancy E Hynes; Heidi A Lane
Journal:  Nat Rev Cancer       Date:  2005-05       Impact factor: 60.716

Review 8.  Epidermal growth factor receptor biology in head and neck cancer.

Authors:  Shailaja Kalyankrishna; Jennifer R Grandis
Journal:  J Clin Oncol       Date:  2006-06-10       Impact factor: 44.544

9.  Design, synthesis and antimicrobial properties of non-hemolytic cationic alpha-cyclopeptoids.

Authors:  Daniela Comegna; Monica Benincasa; Renato Gennaro; Irene Izzo; Francesco De Riccardis
Journal:  Bioorg Med Chem       Date:  2010-01-15       Impact factor: 3.641

10.  On-resin N-methylation of cyclic peptides for discovery of orally bioavailable scaffolds.

Authors:  Tina R White; Chad M Renzelman; Arthur C Rand; Taha Rezai; Cayla M McEwen; Vladimir M Gelev; Rushia A Turner; Roger G Linington; Siegfried S F Leung; Amit S Kalgutkar; Jonathan N Bauman; Yizhong Zhang; Spiros Liras; David A Price; Alan M Mathiowetz; Matthew P Jacobson; R Scott Lokey
Journal:  Nat Chem Biol       Date:  2011-09-25       Impact factor: 15.040

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.